Skip to main content

Advertisement

Table 1 Demographic characterization, CSF results, and NfL concentrations in the diagnostic groups

From: Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

  Controls MCI-AD ADD
N (male + female) 41 (22 + 19) 25 (10 + 15) 33 (13 + 20)
Age (years) 52.5 ± 13.1 71.3 ± 8.4 70.8 ± 7.6
MMSE 29.3 ± 0.9a 26.7 ± 2.1b 21.2 ± 3.4
CSF Aβ1–42 (pg/mL) 1025 ± 308 585 ± 116 536 ± 114
CSF Aβ1–40 (pg/mL) 13,598 ± 4046 19,171 ± 5689 15,309 ± 4172
CSF Aβ42/40 0.076 ± 0.01 0.032 ± 0.01 0.036 ± 0.006
CSF Tau (pg/mL) 198 ± 64.4 631 ± 214 558 ± 178
CSF pTau181 (pg/mL) 37.3 ± 12.1 101.4 ± 29.8 89.9 ± 18.4
Plasma NfL (pg/mL) 22.0 ± 12.4 38.1 ± 15.9 49.1 ± 28.4
  1. Values are shown as averages ± standard deviations or as numbers per group
  2. amyloid β, AD Alzheimer’s disease, ADD Alzheimer’s disease dementia, CSF cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini Mental State Examination, NfL neurofilament light chain
  3. aAvailable in 22 cases
  4. bAvailable in 23 cases